Venetoclax is an oral BH3 mimetic highly selective for BCL-2 without targeting BCL-XL, with dramatic activity in CLL, notably independent of TP53 mutation (23–25). This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.